Q-omics provides the consensus-scored CDCA4 profile across patient tissues and cancer cell-line models. CDCA4 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CDCA4 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, CDCA4 RNA expression shows 21,774 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, COAD, and LUAD as cancer lineages where CDCA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDCA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDCA4 survival associations across molecular data types. CDCA4 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDCA4 RNA expression–survival associations across cancer types. High CDCA4 expression shows unfavorable associations in MESO, ACC, KIRP, LIHC, PAAD and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CDCA4 RNA expression.
This table summarizes CDCA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CDCA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDCA4 shows higher tumor expression in COAD, HNSC, BLCA, KIRP, LUAD and THCA. The COAD box plot shows higher CDCA4 RNA expression in tumor versus normal tissue (log2 FC = +2.014, t-test p < 0.001).
This table shows molecular features associated with CDCA4 in patient tissues and cancer cell lines. In patient samples, CDCA4 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CDCA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
